leading glp-1 treatments for diabetes 2025 What is the pipeline future medications for obesity? Long-term Success of GLP-1s Hinges

Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): New perspectives for a fairy-tale ending

Many patients benefit from a second round of GLP-1 therapy or a longer initial treatment duration

Ready for a Slimmer You

A recent cohort study looked at the physiological differences between people with MCS who had no other comorbidities (e.g., no fibromyalgia or autoimmune diseases) and an age- and health-matched control group

This limited window exists because exposure to air, light, and temperature fluctuations gradually oxidizes and destabilizes the peptide compound

Before starting intensive behavioral therapy for obesity, its crucial to keep a food diary for several days and discuss current diet and fitness habits with a healthcare provider